1052 related articles for article (PubMed ID: 9502300)
21. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma.
Shepherd JD; Barnett MJ; Connors JM; Spinelli JJ; Sutherland HJ; Kingemann HG; Nantel SH; Reece DE; Currie CJ; Phillips GL
Bone Marrow Transplant; 1993 Dec; 12(6):591-6. PubMed ID: 8136743
[TBL] [Abstract][Full Text] [Related]
23. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of adults with acute myelogenous leukemia in remission given 550 cGy of single-exposure total body irradiation, cyclophosphamide, and unrelated donor bone marrow transplants.
Hallemeier C; Girgis M; Blum W; Brown R; Khoury H; Goodnough LT; Vij R; Devine S; Wehde M; Postma S; Lin HS; Dipersio J; Adkins D
Biol Blood Marrow Transplant; 2004 May; 10(5):310-9. PubMed ID: 15111930
[TBL] [Abstract][Full Text] [Related]
25. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
26. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.
Sobecks RM; Daugherty CK; Hallahan DE; Laport GF; Wagner ND; Larson RA
Bone Marrow Transplant; 2000 Apr; 25(8):807-13. PubMed ID: 10808200
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
28. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma.
Hänel M; Kröger N; Sonnenberg S; Bornhäuser M; Krüger W; Kroschinsky F; Hänel A; Metzner B; Birkmann J; Schmid B; Hoffknecht MM; Fiedler F; Ehninger G; Zander AR
Ann Hematol; 2002 Feb; 81(2):96-102. PubMed ID: 11907790
[TBL] [Abstract][Full Text] [Related]
29. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy.
Vaughan WP; Dennison JD; Reed EC; Klassen L; McGuire TR; Sanger WG; Kumar PP; Warkentin PI; Gordon BG; Bierman PJ
Bone Marrow Transplant; 1991 Dec; 8(6):489-95. PubMed ID: 1790429
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
31. Fractionated total body irradiation plus high-dose VP-16 prior to allogeneic bone marrow transplantation in children with poor risk acute leukaemias.
Suttorp M; Schmitz N; Leuschner S; Appelt M; Rister M; Schaub J
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():144-8. PubMed ID: 2697428
[TBL] [Abstract][Full Text] [Related]
32. Treatment of infant leukemia with busulfan, cyclophosphamide +/- etoposide and bone marrow transplantation.
Emminger W; Emminger-Schmidmeier W; Haas OA; Urban C; Ambros P; Peters C; Mann G; Fink FM; Ferstl G; Höcker P
Bone Marrow Transplant; 1992 May; 9(5):313-8. PubMed ID: 1617314
[TBL] [Abstract][Full Text] [Related]
33. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia.
Toze CL; Shepherd JD; Connors JM; Voss NJ; Gascoyne RD; Hogge DE; Klingemann HG; Nantel SH; Nevill TJ; Phillips GL; Reece DE; Sutherland HJ; Barnett MJ
Bone Marrow Transplant; 2000 Mar; 25(6):605-12. PubMed ID: 10734294
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized comparison of total body irradiation-etoposide versus busulfan-cyclophosphamide as preparatory regimens for bone marrow transplantation in patients with leukemia who were not in first remission: a Southwest Oncology Group study.
Blume KG; Kopecky KJ; Henslee-Downey JP; Forman SJ; Stiff PJ; LeMaistre CF; Appelbaum FR
Blood; 1993 Apr; 81(8):2187-93. PubMed ID: 8471778
[TBL] [Abstract][Full Text] [Related]
35. CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Ball E; Cook D; Andresen S; Kuczkowski E; Bolwell B
Bone Marrow Transplant; 2005 Feb; 35(3):247-52. PubMed ID: 15580282
[TBL] [Abstract][Full Text] [Related]
36. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
37. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma.
Bernard M; Dauriac C; Drénou B; Leberre C; Branger B; Fauchet R; Le Prisé PY; Lamy T
Bone Marrow Transplant; 1999 Feb; 23(4):329-33. PubMed ID: 10100576
[TBL] [Abstract][Full Text] [Related]
38. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
[TBL] [Abstract][Full Text] [Related]
39. New conditioning regimens for high risk marrow transplants.
Jones RJ; Santos GW
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors affecting leukemia relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated TBI.
Zapatero A; Martín de Vidales C; Pinar B; Rodríguez F; Marín A; Cerezo L; Domínguez P; Pérez Torrubia A
Bone Marrow Transplant; 1996 Sep; 18(3):591-6. PubMed ID: 8879623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
